Seclidemstat
Desmoplastic Small Round Cell Tumor
Explore 10 assets in Desmoplastic Small Round Cell Tumor →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Salarius Pharmaceuticals, LLC
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03600649CT.gov Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Desmoplastic Small Round Cell Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Seclidemstat (this asset) | Salarius Pharmaceuticals, LLC | P1 | CC · 43 |
| Cyclophosphamide | St. Jude Children's Research Hospital | P2 | B |
| Fludarabine | St. Jude Children's Research Hospital | P2 | B |
| Imatinib | National Cancer Institute (NCI) | P2 | B |
| Etoposide | M.D. Anderson Cancer Center | P2 | CCC |
| Melphalan | M.D. Anderson Cancer Center | P2 | CCC |
| Tacrolimus | M.D. Anderson Cancer Center | P2 | CCC |
| Thiotepa | M.D. Anderson Cancer Center | P2 | CCC |
| Cis-Diamminedichloroplatinum Ii | Mayo Clinic | P1 | CCC |
+18 more in the Desmoplastic Small Round Cell Tumor cohort
Other indications for Seclidemstat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myxoid Liposarcoma | — | P1 | CC · 43 |
| Soft Tissue Sarcoma | — | P1 | CC · 43 |
| Extraskeletal Myxoid Chondrosarcoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Seclidemstat in Desmoplastic Small Round Cell Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/seclidemstat-desmoplastic-small-round-cell-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →